3Russell RG. Bisphosphonates : From bench to bedside [J]. Ann NY Acad Sci,2006,1068( 1 ) :367 -401. 被引量：1
4Nancollas GH, Tang R, Phipps R J, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite[ J]. Bone ,2006:38 (5) :617 - 627. 被引量：1
5Coxon FP,Helfrich MH,Van' t Hof R,et al. Protein geranylgera- nylation is required for osteoclast formation, function, and survival : Inhibition by bis - phosphonates and GGTI - 298 [ J ]. J Bone Miner Res ,2000,15 ( 8 ) : 1467 - 1476. 被引量：1
6Gasser JA, Ingold P, Venturiere A, et al. Long - term protective effects of Zoledronic acid on canxellous and cortical bone in the ovariectomized rat [J]. J Bone Miner Res, 2008,23 ( 4 ) : 544 - 551. 被引量：1
7Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and phar- macodynamics of Zoledronic acid in cancer patients with bone metastases[ J]. J Clin Pharmaco1,2002,42( 11 ) :1228 -1236. 被引量：1
8Pietrzik K, Bailey L, Shane B. Folic acid and L- 5 -methyhetra- hydrofolate:Comparison of clinical pharmacokinetics and pharma- codynamics [ J ]. Clin Pharmacokinet,2010,49 ( 8 ) :535 - 548. 被引量：1
9Briot K,Cortet B,Thomas T,et al. 2012 update of French guide- lines for the pharmacological treatment of postmenopausal osteopo- rosis[J]. Joint Bone Spine,2012,79 ( 3 ) :304 - 313. 被引量：1
10Black DM, Delmas PD, Eastell R, et al. Once - yearly zoledronic acid for treatment of postmenopausal osteoporosis [ J ]. N Engl J Med,2007,356 ( 18 ) : 1809 - 1822. 被引量：1
